The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.

The latest price target for Biofrontera (NASDAQ: BFRI) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $18.00 expecting BFRI to rise to within 12 months (a possible 99.12% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Biofrontera (NASDAQ: BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $0.00 to $18.00. The current price Biofrontera (BFRI) is trading at is $9.04, which is within the analyst’s predicted range.